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Dissertation Summary 
 
There is scanty data on the nature and extent of co-infection with hepatitis B virus (HBV) and 
Human Immunodeficiency virus (HIV) in Zimbabwe. Co-infection with HBV and HIV is associated 
with HBV reactivation, HBV persistence, severe liver disease, liver fibrosis, cirrhosis, liver cancer 
and early death (Thio et al., 2002; McMahon, 2009; Kew, 2012). The current study determined the 
prevalence of HBV-HIV coinfection among untreated HIV patients in Harare city. It also assessed 
whether patient demographics like age and sex, host immune status indicated by CD4+ T cell 
counts and liver fibrosis indicated by non-invasive markers FIB-4 and APRI, were associated with 
HBV-HIV co-infection. In addition, HBV and HIV genetic variants in the Harare cohort were 
sequenced and analyzed by phylogenetic analysis to identify genotypes and variants such as drug 
resistance mutations. Of the 176 pre-HIV treatment adults recruited, 19 (10.8%) were positive for 
hepatitis B surface antigen (HBsAg) i.e. were HBV-HIV co-infected, notably among male patients 
(p=0.009). Interestingly, lower CD4+ T cell counts (p=0.016) and higher fibrosis markers FIB-4 and 
APRI (p=0.0001) were associated with HBV-HIV co-infection in this cohort. Out of the 19 
HBsAg-positive samples,12 had detectable HBV DNA and of these, 4 were successfully 
sequenced in the basal core promoter/precore (BCP/PC) and small surface antigen regions while 
3, with high HBV viral load, in the whole HBV genome. All the 7 sequenced HBV isolates were 
classified as HBV subgenotype A1 by phylogenetic analysis. BCP/PC mutations like 1762T and 
1764A, associated with liver cancer development, were identified. Mutations in the small surface 
antigen that are potentially associated with false positivity by some diagnostic assays i.e M133I/T 
and D144G were detected in 2 out of 7 isolates. Surprisingly, PreS2 deletion mutations were also 
identified in 2 out of the 3 full HBV sequences, one of which concurrently had a PreS1 deletion, all 
associated with intrahepatic HBsAg retention, ER stress and liver cancer. For HIV, 164 isolates 
were successfully sequenced in the protease-reverse transcriptase regions. All except one isolate 
(99.4%) were classified as HIV-1 subtype C. Interestingly, 9.8% (16/164) of these HIV isolates had 
drug resistance mutations associated with non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) like the K103N, Y181C, predominantly among female patients suggesting undisclosed 
antiviral exposure or transmitted drug resistance. In conclusion, our data showed a high 
prevalence of HBV-HIV coinfection in our HIV cohort therefore rigorous HBV screening and 
treatment with dual active drugs e.g. Tenofovir-based regimens were recommended.  
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